Autologous Stem Cell Transplant for AL Amyloidosis

Abstract EN

AL amyloidosis is caused by clonal plasma cells that produce immunoglobulin light chains which misfold and get deposited as amyloid fibrils.

Therapy directed against the plasma cell clone leads to clinical benefit.

Melphalan and corticosteroids have been the mainstay of treatment for a number of years and the recent availability of other effective agents (IMiDs and proteasome inhibitors) has increased treatment options.

Autologous stem cell transplant (ASCT) has been used in the treatment of AL amyloidosis for many years.

It is associated with high rates of hematologic response and improvement in organ function.

However, transplant carries considerable risks.

Careful patient selection is important to minimize transplant related morbidity and mortality and ensure optimal patient outcomes.

As newer more affective therapies become available the role and timing of ASCT in the overall treatment strategy of AL amyloidosis will need to be continually reassessed.